摘要
目的 观察兰他隆 (Lentaron)治疗绝经后复发转移乳腺癌的疗效和副作用。方法 34例绝经后复发转移乳腺癌患者给予兰他隆 2 5 0mg肌肉注射 ,每 2周 1次 ,至少 1个月。结果 34例可评价疗效和毒副作用的患者中 ,部分缓解 (PR) 5例 ,占 14 .7% ;稳定 (SD) 2 0例 ,占 5 8.8% ,其中病情稳定≥ 6个月者 12例 ,占 35 .3% ;临床获益患者 (PR +SD≥ 6个月 ) 17例 ,占 5 0 .0 % ;病情进展 9例 ,占2 6 .5 %。骨、软组织和内脏转移有效率依次为 30 .8% (4/ 13)、13.6 % (3/ 2 2 )和 5 .3% (1/ 19)。治疗中无严重不良反应。结论 兰他隆治疗绝经后复发转移乳腺癌有一定疗效 ,药物不良反应轻 。
Objective To evaluate the efficacy and adverse effects of lentaron for postmenopausal patients with recurrent and metastatic breast cancer. Methods Thirty four patients with recurrent and metastatic breast cancer received 250 mg lentaron by intramuscular injection every 2 weeks for at least one month. Results In 34 patients who were evaluable for efficacy and toxicity, the complete response rate (CR), partial response rate (PR), disease stabilization rate (SD) and progressive disease rate (PD) were 0%, 14.7%, 58.8% and 26.5% . The clinical benefit rate (CR+PR+SD≥6 months) was 50.0% (17/34) with 12 patients ( 35.3% ) having SD for at least 6 months. The response rates for bone, soft tissue and visceral metastasis were 28.6% (4/14) , 13.6% (3/22) and 5.3% (1/19), respectively. There were no severe adverse effects in the treatment by lentaron. Conclusion Lentaron is a well tolerated agent with reasonable efficacy but low toxicity for postmenopausal patients with recurrent and metastatic breast cancer.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2002年第5期511-513,共3页
Chinese Journal of Oncology
